Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions' stock price has been influenced by several events over the past six months. The company's Q1 2026 earnings report showed revenue and EPS surpassing estimates, leading to a stock increase. A new stock repurchase program of up to $50 million was authorized. A lawsuit against the former CEO for insider trading caused a stock slump. The company received approval for an expanded indication of ACAM2000® and secured a long-term strategic manufacturing contract with SAB Biotherapeutics. Over the past year, the stock price has changed by 43.080%, with a 52-week range between $5.305 and $14.060.

While detailed seasonality for all products is not extensively outlined, there is a notable seasonality factor for Emergent BioSolutions' naloxone franchise. The second fiscal quarter (Q2) is the fiscal year-end for approximately 70% of states, which influences demand for naloxone products. There is sustained demand in the global market for biodefense products. The company faces risks, including potential erosion of the NARCAN franchise due to increased generic competition and reliance on government contracts for medical countermeasures.

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company focused on developing, manufacturing, and commercializing medical countermeasures and specialty products for public health threats. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Its product portfolio includes Commercial Products, Medical Countermeasure (MCM) Products, and Services. Key commercial products are NARCAN® and KLOXXADO® Nasal Sprays. The MCM segment addresses biological, chemical, and emerging infectious disease threats. The Services segment provides contract development and manufacturing services.

Emergent BioSolutions has research, development, and manufacturing facilities across North America, Europe, and Asia. Its primary U.S. manufacturing sites are in Maryland and Michigan, with the corporate office in Gaithersburg, Maryland. Other key locations include Canton, Massachusetts; Dublin, Ireland; London, UK; Washington, D.C.; and Winnipeg, Canada. The majority of its revenue comes from the United States.

Emergent BioSolutions' brand reputation has been negatively impacted by legal and operational issues in the past year. The lawsuit against former CEO Robert G. Kramer for insider trading and the company's settlement highlighted past manufacturing and contamination problems from 2020-2021, where COVID-19 vaccines were contaminated, leading to FDA citations and discarded doses. This has likely cast a negative light on the company's manufacturing quality control and executive oversight.

Emergent BioSolutions' ownership is primarily institutional, with institutional investors holding approximately 43.79% to 83.61% of the company's stock. Major institutional holders include BlackRock, Inc., Oak Hill Advisors, L.P., and The Vanguard Group, Inc. Individual insiders hold approximately 2% to 9.01% of the shares. Public companies and retail investors hold around 13.50% to 50.88%. Insider trading activity in the past six months has shown more sales than purchases by insiders.